NAS:IMGN (USA)
Business Description
Immunogen Inc
NAICS : 325412
SIC : 2834
830 Winter Street, Waltham, MA, USA, 02451
Compare
Compare
Traded in other countries / regions
IMU.Germany
•
IMGN.Mexico
•
0A8K.UK
•
IMGN.USA
Description
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.83 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.09 | |||||
| Beneish M-Score | -3.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.9 | |||||
| 3-Year EBITDA Growth Rate | 17.6 | |||||
| 3-Year EPS without NRI Growth Rate | 17.5 | |||||
| 3-Year FCF Growth Rate | 12.3 | |||||
| 3-Year Book Growth Rate | 172.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.89 | |||||
| 9-Day RSI | 62.73 | |||||
| 14-Day RSI | 60.59 | |||||
| 6-1 Month Momentum % | -7.89 | |||||
| 12-1 Month Momentum % | -13.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.52 | |||||
| Quick Ratio | 4.52 | |||||
| Cash Ratio | 4.29 | |||||
| Days Sales Outstanding | 5.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -170.72 | |||||
| Net Margin % | -179.64 | |||||
| ROE % | -78.19 | |||||
| ROA % | -39.61 | |||||
| ROIC % | -186.13 | |||||
| ROC (Joel Greenblatt) % | -906.76 | |||||
| ROCE % | -50.35 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.42 | |||||
| PB Ratio | 4.81 | |||||
| Price-to-Tangible-Book | 4.82 | |||||
| EV-to-EBIT | -5.51 | |||||
| EV-to-EBITDA | -5.58 | |||||
| EV-to-Forward-EBITDA | -3.96 | |||||
| EV-to-Revenue | 9.46 | |||||
| EV-to-Forward-Revenue | 10.29 | |||||
| EV-to-FCF | -4.52 | |||||
| Price-to-Median-PS-Value | 1.42 | |||||
| Price-to-Net-Current-Asset-Value | 5.45 | |||||
| Price-to-Net-Cash | 5.99 | |||||
| Earnings Yield (Greenblatt) % | -18.15 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:IMGN
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 89.442 | ||
| EPS (TTM) ($) | -0.69 | ||
| Beta | 0.55 | ||
| Volatility % | 52.36 | ||
| 14-Day RSI | 60.59 | ||
| 14-Day ATR ($) | 0.353346 | ||
| 20-Day SMA ($) | 5.109 | ||
| 12-1 Month Momentum % | -13.88 | ||
| 52-Week Range ($) | 3.095 - 7.77 | ||
| Shares Outstanding (Mil) | 220.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunogen Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||